Equities research analysts forecast that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will post $5.63 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Teva Pharmaceutical Industries Limited’s earnings. The lowest sales estimate is $5.58 billion and the highest is $5.72 billion. Teva Pharmaceutical Industries Limited posted sales of $5.56 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 1.3%. The firm is scheduled to report its next quarterly earnings results on Tuesday, November 21st.

According to Zacks, analysts expect that Teva Pharmaceutical Industries Limited will report full year sales of $5.63 billion for the current financial year, with estimates ranging from $22.40 billion to $23.01 billion. For the next fiscal year, analysts forecast that the company will post sales of $22.10 billion per share, with estimates ranging from $21.39 billion to $22.90 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the prior year, the company earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% on a year-over-year basis.

A number of research firms have recently commented on TEVA. Credit Suisse Group AG set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective for the company in a report on Monday, July 24th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Three research analysts have rated the stock with a sell rating, nineteen have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus target price of $37.69.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cribstone Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth $106,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the last quarter. Finally, FNY Managed Accounts LLC bought a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. 56.04% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.97 on Wednesday. The company’s 50 day moving average is $28.78 and its 200-day moving average is $31.30. The company’s market cap is $18.26 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be paid a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is currently -18.95%.

ILLEGAL ACTIVITY NOTICE: “$5.63 Billion in Sales Expected for Teva Pharmaceutical Industries Limited (TEVA) This Quarter” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/5-63-billion-in-sales-expected-for-teva-pharmaceutical-industries-limited-teva-this-quarter/1492849.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.